Do analysts rate EXEL or GMTX?

Exelixis presently has a consensus price target of $50.07, indicating a potential downside of 15.33%. Given Exelixis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Exelixis is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exelixis 1 Sell rating(s) 12 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.35 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer GMTX or BMRN?

BioMarin Pharmaceutical has a consensus target price of $89.17, indicating a potential upside of 34.24%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioMarin Pharmaceutical 1 Sell rating(s) 6 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 2.74

Do analysts recommend GMTX or ARWR?

Arrowhead Pharmaceuticals has a consensus price target of $98.42, indicating a potential upside of 13.79%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arrowhead Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.62

Do analysts prefer GMTX or HALO?

Halozyme Therapeutics has a consensus target price of $91.20, suggesting a potential downside of 17.66%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Halozyme Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.62

Do analysts prefer GMTX or MDGL?

Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 28.94%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.78

Gemini Therapeutics (GMTX) Competitors

$80.05 +1.38 (+1.75%)

As of 09/2/2026

Compare

GMTX vs. EXEL, BMRN, ARWR, HALO, and MDGL

Should you buy Gemini Therapeutics stock or one of its competitors? Gemini Therapeutics's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Arrowhead Pharmaceuticals (ARWR), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gemini Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Exelixis has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Exelixis has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.31	$782.57M	$3.18	18.59
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Exelixis presently has a consensus price target of $50.07, indicating a potential downside of 15.33%. Given Exelixis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Exelixis is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

85.3% of Exelixis shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Gemini Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Exelixis had 28 more articles in the media than Gemini Therapeutics. MarketBeat recorded 28 mentions for Exelixis and 0 mentions for Gemini Therapeutics. Exelixis' average media sentiment score of 0.83 beat Gemini Therapeutics' score of 0.00 indicating that Exelixis is being referred to more favorably in the media.

Company	Overall Sentiment
Exelixis	Positive
Gemini Therapeutics	Neutral

Summary

Exelixis beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to BioMarin Pharmaceutical?

Gemini Therapeutics (NASDAQ:GMTX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Gemini Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
BioMarin Pharmaceutical	$3.22B	3.99	$348.90M	$0.37	179.54

Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has a consensus target price of $89.17, indicating a potential upside of 34.24%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

In the previous week, BioMarin Pharmaceutical had 30 more articles in the media than Gemini Therapeutics. MarketBeat recorded 30 mentions for BioMarin Pharmaceutical and 0 mentions for Gemini Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.98 beat Gemini Therapeutics' score of 0.00 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
BioMarin Pharmaceutical	Positive

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Arrowhead Pharmaceuticals has a consensus price target of $98.42, indicating a potential upside of 13.79%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arrowhead Pharmaceuticals	$669.50M	18.20	-$1.63M	-$2.25	N/A

In the previous week, Arrowhead Pharmaceuticals had 27 more articles in the media than Gemini Therapeutics. MarketBeat recorded 27 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.56 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Arrowhead Pharmaceuticals	Positive

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Halozyme Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Halozyme Therapeutics	$1.40B	9.00	$316.89M	$3.35	33.06

In the previous week, Halozyme Therapeutics had 36 more articles in the media than Gemini Therapeutics. MarketBeat recorded 36 mentions for Halozyme Therapeutics and 0 mentions for Gemini Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.15 beat Gemini Therapeutics' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Halozyme Therapeutics	Positive

Halozyme Therapeutics has a consensus target price of $91.20, suggesting a potential downside of 17.66%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Gemini Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Summary

Halozyme Therapeutics beats Gemini Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Madrigal Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Gemini Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Madrigal Pharmaceuticals	$958.40M	13.08	-$288.28M	-$12.89	N/A

Gemini Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Gemini Therapeutics' return on equity of -38.78% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 28.94%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Madrigal Pharmaceuticals had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for Madrigal Pharmaceuticals and 0 mentions for Gemini Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 1.26 beat Gemini Therapeutics' score of 0.00 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Madrigal Pharmaceuticals	Positive

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

Summary

Madrigal Pharmaceuticals beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.47B	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-80.05	12.72	273.59	25.45
Price / Sales	N/A	1,361.39	675.80	123.67
Price / Cash	N/A	105.29	76.98	52.10
Price / Book	27.70	16.29	12.89	6.14
Net Income	-$71.87M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-3.17%	-1.38%	-0.33%	-1.47%
1 Month Performance	3.96%	11.06%	6.51%	2.47%
1 Year Performance	30.37%	53.71%	25.19%	15.84%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$80.05 +1.8%	N/A	+31.9%	$3.47B	N/A	N/A	30	High Trading Volume
EXEL Exelixis	2.9024 of 5 stars	$56.10 -1.1%	$50.07 -10.8%	+57.4%	$14.05B	$2.32B	17.64	1,077	Analyst Upgrade
BMRN BioMarin Pharmaceutical	4.8935 of 5 stars	$65.61 -0.8%	$88.79 +35.3%	+13.3%	$12.80B	$3.41B	177.32	3,221	Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.1071 of 5 stars	$89.12 +0.3%	$97.33 +9.2%	+232.4%	$12.52B	$829.45M	N/A	400	News Coverage Analyst Forecast
HALO Halozyme Therapeutics	3.7973 of 5 stars	$107.06 -2.1%	$91.20 -14.8%	+49.5%	$12.41B	$1.40B	31.96	390	Trending News Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. EXEL, BMRN, ARWR, HALO, and MDGL

How does Gemini Therapeutics compare to Exelixis?

Summary

How does Gemini Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Gemini Therapeutics compare to Halozyme Therapeutics?

Summary

How does Gemini Therapeutics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. EXEL, BMRN, ARWR, HALO, and MDGL

How does Gemini Therapeutics compare to Exelixis?

Which has more volatility & risk, EXEL or GMTX?

Which has higher earnings and valuation, EXEL or GMTX?

Do analysts rate EXEL or GMTX?

Do insiders and institutionals have more ownership in EXEL or GMTX?

Is EXEL or GMTX more profitable?

Does the media prefer EXEL or GMTX?

Summary

How does Gemini Therapeutics compare to BioMarin Pharmaceutical?

Is GMTX or BMRN more profitable?

Which has stronger earnings and valuation, GMTX or BMRN?

Which has more risk & volatility, GMTX or BMRN?

Do analysts prefer GMTX or BMRN?

Does the media favor GMTX or BMRN?

Do institutionals & insiders have more ownership in GMTX or BMRN?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Do analysts recommend GMTX or ARWR?

Which has more risk & volatility, GMTX or ARWR?

Is GMTX or ARWR more profitable?

Which has stronger earnings & valuation, GMTX or ARWR?

Does the media favor GMTX or ARWR?

Do institutionals and insiders have more ownership in GMTX or ARWR?

Summary

How does Gemini Therapeutics compare to Halozyme Therapeutics?

Which has more volatility and risk, GMTX or HALO?

Which has higher earnings & valuation, GMTX or HALO?

Does the media favor GMTX or HALO?

Do analysts prefer GMTX or HALO?

Do insiders and institutionals have more ownership in GMTX or HALO?

Is GMTX or HALO more profitable?

Summary

How does Gemini Therapeutics compare to Madrigal Pharmaceuticals?

Which has higher earnings & valuation, GMTX or MDGL?

Is GMTX or MDGL more profitable?

Do insiders & institutionals believe in GMTX or MDGL?

Do analysts prefer GMTX or MDGL?

Does the media prefer GMTX or MDGL?

Which has more volatility & risk, GMTX or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools